GlycoMimetics, Inc. (GLYC) was a big mover last session, as its shares rose over 12% on the day. The upside was driven by the news that Pfizer Inc. (PFE) will pay $20 million to GlycoMimetics following the initiation of a phase 3 trial on Rivipansel. This led to far more shares changing hands than in a normal session. Yesterday’s rally breaks the recent trend for the company, as the stock is now trading above the volatile price range of $7.61 to $8.54 in the past one-month time frame.
Over the last 30 days, the company did not witness any estimate revision and the Zacks Consensus Estimate also remained unchanged. Yesterday’s price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
GlycoMimetics currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Be the first to comment